ArticleScientific reports2025
CA-125/albumin and lymphocyte/albumin ratios as complementary biomarkers to the malignancy risk index in ovarian cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the usability of the lymphocyte/albumin (L/A) ratio as a potential biomarker in determining the risk of malignancy in ovarian cancer and to make a comparative analysis of this ratio with the Risk of Malignancy Index (RMI). Designed as a retrospective study, this study was conducted with 130 patients who underwent surgery for ovarian mass between 2020 and 2023. Demographic, clinical and laboratory data (CA-125, albumin, lymphocytes, neutrophils, monocytes) of the patients were collected retrospectively. L/A ratio, CA-125/albumin, neutrophil/lymphocyte (N/L) and monocyte/lymphocyte (M/L) ratios were calculated. RMI was calculated using ultrasound findings, menopausal status and CA-125 levels. Statistical analyses were performed with IBM SPSS 27 package program and diagnostic accuracy was evaluated using ROC curve analysis. RMI, CA-125, monocyte, neutrophil, CA-125/albumin, N/L and M/L values were significantly higher in the malignant patient group than in the benign patient group (p < 0.05). The L/A ratio was lower in the malignant patient group (p = 0.035). The CA-125/albumin ratio had the highest diagnostic accuracy (AUC = 0.13, p < 0.001). The AUC value of the L/A ratio was calculated as 0.61. This study showed that L/A ratio can be used as a potential biomarker in determining the risk of malignancy in ovarian cancer. Especially the high diagnostic accuracy of CA-125/albumin ratio suggests that this combination should be evaluated as a complementary method to RMI. Larger-scale studies are needed to elucidate the role of inflammatory biomarkers in the diagnosis of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.